JP2024530344A5 - - Google Patents

Info

Publication number
JP2024530344A5
JP2024530344A5 JP2024514000A JP2024514000A JP2024530344A5 JP 2024530344 A5 JP2024530344 A5 JP 2024530344A5 JP 2024514000 A JP2024514000 A JP 2024514000A JP 2024514000 A JP2024514000 A JP 2024514000A JP 2024530344 A5 JP2024530344 A5 JP 2024530344A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
administration
iptacopan
period
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024514000A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024530344A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2022/058275 external-priority patent/WO2023037218A1/en
Publication of JP2024530344A publication Critical patent/JP2024530344A/ja
Publication of JP2024530344A5 publication Critical patent/JP2024530344A5/ja
Pending legal-status Critical Current

Links

JP2024514000A 2021-09-07 2022-09-02 加齢黄斑変性の処置のためのb因子阻害剤の使用 Pending JP2024530344A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163241169P 2021-09-07 2021-09-07
US63/241,169 2021-09-07
PCT/IB2022/058275 WO2023037218A1 (en) 2021-09-07 2022-09-02 Use of factor b inhibitors for the treatment of age-related macular degeneration

Publications (2)

Publication Number Publication Date
JP2024530344A JP2024530344A (ja) 2024-08-16
JP2024530344A5 true JP2024530344A5 (enExample) 2025-09-10

Family

ID=83457168

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024514000A Pending JP2024530344A (ja) 2021-09-07 2022-09-02 加齢黄斑変性の処置のためのb因子阻害剤の使用

Country Status (5)

Country Link
US (1) US20240398779A1 (enExample)
EP (1) EP4398906A1 (enExample)
JP (1) JP2024530344A (enExample)
CN (1) CN117915915A (enExample)
WO (1) WO2023037218A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250161347A1 (en) 2023-11-22 2025-05-22 Flagship Pioneering Innovations Vii, Llc Methods and compositions for treating non-alcoholic fatty liver disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3425B1 (ar) 2013-07-15 2019-10-20 Novartis Ag مشتقات البابيريدينيل-اندول واستخدامها كعامل متمم لمثبطات b

Similar Documents

Publication Publication Date Title
JP7358221B2 (ja) 老視を治療するための組成物及び方法
Konstas et al. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma
JP2009511618A (ja) 中度から重度のむずむず脚症候群(rls)を治療するためのプラミペキソールの使用
KR20040100844A (ko) 눈에 국소적으로 사용하기 위한 브리모니딘과 티몰롤의조합물
JP2012136523A (ja) テルビナフィンを含有する医薬組成物およびその使用
WO2022221195A1 (en) Treatment of essential tremor
GB2571644A (en) Composition containing ursodeoxycholic acid for prevention or treatment of visual impairment
CN102724878A (zh) 在重度抑郁症患者中提供体重减轻疗法的方法
CN111032158A (zh) 用于治疗抑郁的nk-1拮抗剂组合物和方法
RS67956B1 (sr) Troriluzol za upotrebu u lečenju spinocerebelarne ataksije 3 (sca3)
JP2018024677A (ja) ラキニモドを使用する眼炎症性疾患の治療
CN109316480A (zh) 组合als疗法
Duvoisin Problems in the treatment of parkinsonism
KR20180034442A (ko) 아캄프로세이트와 d-사이클로세린을 사용한 병용 치료
JP2023548429A5 (enExample)
Canonica et al. Topical azelastine in perennial allergic conjunctivitis
JP4786127B2 (ja) 色素沈着改善治療薬
JP2024516003A5 (enExample)
WO2010117077A1 (ja) シロリムス誘導体を有効成分として含有する網脈絡膜疾患の治療剤
JP5735968B2 (ja) 眼痛を処置または予防するためのケトロラクトロメタミン組成物
US20200297707A1 (en) Methods and Compositions to Inhibit Symptoms Associated with Viral Upper Respiratory Tract Infections
US20240277662A1 (en) Administration of a Compound to Individuals with Hepatic Impairment
CN103635194B (zh) 用于治疗早泄的药物组合物以及用于治疗早泄的方法
JP2024530344A (ja) 加齢黄斑変性の処置のためのb因子阻害剤の使用
CN117956959A (zh) 用于治疗睡眠呼吸暂停的方法和组合物